Table 3 Means (and 95% CI:s) of quality of life and mental health rating scores for subjects who completed the study.
Placebo (n = 14) | Paroxetine (n = 23) | Placebo-Paroxetine | ||
|---|---|---|---|---|
Mean (95% CI) | Mean (95% CI) | Mean difference (95% CI) | p | |
SF-36 | ||||
Baseline | 51.2 (42.6 to 59.8) | 56.2 (48.6 to 63.7) | -4.7 (-16.3 to 6.4) | 0.381 |
3 months | 59.1 (51.2 to 67.0) | 70.1 (63.4 to 76.7) | -11.0 (-21.4 to -0.6) | 0.039 |
6 months | 56.9 (47.5 to 66.2) | 65.8 (58.5 to 73.6) | -8.9 (-20.8 to 2.9) | 0.135 |
HADS total score | ||||
Baseline | 15.8 (12.5 to 19.1) | 14.0 (11.7 to 16.2) | 1.8 (-1.9 to 5.6) | 0.327 |
3 months | 11.2 (9.0 to 13.5) | 8.5 (6.6 to 10.4) | 2.8 (-0.2 to 5.7) | 0.066 |
6 months | 12.1 (8.9 to 15.4) | 10.2 (7.6 to 12.7) | 1.9 (-2.2 to 6.1) | 0.351 |
HADS depression score | ||||
Baseline | 8.2 (6.2 to 10.2) | 7.3 (5.8 to 8.7) | 0.9 (-1.4 to 3.4) | 0.416 |
3 months | 5.1 (3.8 to 6.3) | 3.8 (2.7 to 4.9) | 1.3 (-0.4 to 2.9) | 0.129 |
6 months | 6.2 (4.6 to 7.7) | 5.5 (4.3 to 6.6) | 0.7 (-1.2 to 2.7) | 0.448 |
HADS anxiety score | ||||
Baseline | 7.6 (5.8 to 9.4) | 6.7 (5.6 to 7.8) | 0.9 (-1.1 to 2.8) | 0.366 |
3 months | 6.2 (4.8 to 7.6) | 4.6 (3.5 to 5.8) | 1.6 (-0.2 to 3.4) | 0.085 |
6 months | 6.0 (4.0 to 8.0) | 4.7 (3.2 to 6.2) | 1.3 (-1.2 to 3.8) | 0.312 |